Objective: The aim of this study was to compare efficacy and safety of two long-acting
formulations of methylphenidate (MPH) for attention-deficit/hyperactivity disorder (ADHD) in …

Background: The realization that attentiondeficit/hyperactivity disorder (ADHD) often persists
into adulthood has led to increased frequency of diagnosis and treatment in adults. Osmotic …

Objective: Psychostimulants are effective treatments for attention-deficit/hyperactivity
disorder (ADHD) but may be associated with euphoric effects, misuse/diversion, and …

Aim: To determine the differences in the remission rate, recovery rate, functional
improvement, and treatment adherence related to treatment with short‐acting immediate …

Objective To compare the continuity of methylphenidate hydrochloride (MPH) therapy
among youth Medicaid beneficiaries treated for attention-deficit/hyperactivity disorder with …

Objective: The authors evaluated the time course of the treatment effect of Osmotic-Release
Oral System methylphenidate (OROS® MPH) HCl (Concerta®, Raritan, NJ) CII in children …

Objective: To determine the safety and efficacy of PRC-063, a once-daily, multilayer,
extended-release (ER) formulation of methylphenidate (MPH) hydrochloride, in the …

Objective: To test whether an optimal dose of Quillivant XR (methylphenidate extended-
release oral suspension [MEROS]) would significantly reduce symptoms of ADHD in …

We conducted a 3-phase, double-blind, placebo-controlled, parallel study design of osmotic-
release oral system (OROS)-methylphenidate (MPH) in adults (19-60 years of age) with …

Objective: To evaluate the efficacy and safety of individualized dosing within the approved
dose range for osmotic-release oral system (OROS) methylphenidate hydrochloride in …